Boba & Boosting with Portal: PhD to IPO and Beyond!

​Join Armon Sharei, PhD (CEO & founder of Portal, former CEO and founder of SQZ Biotech) for a boba-fueled discussion (followed by networking) on entrepreneurship. We'll cover the ups and downs of SQZ, which raised over $400M and had 3 clinical trials, what it took to go from PhD project to IPO, and how the lessons are being channeled into the next generation. Now the  platform at Portal is enabling new frontiers in cell engineering and analytics through its simple, scalable approach to intracellular delivery. 

Portal is an early-stage biotech company based in Boston, MA. The company, founded in 2023, is focused on commercializing a next generation cell engineering platform to enable novel cell therapies and unique assays for drug discovery. Portal's core technology relies on the rapid mechanical deformation of cells to temporarily disrupt the cell membrane and enable delivery of multiple cargos into cells simultaneously. The company has established over 50 partnerships to date, including with a majority of the top 10 pharma, and is implementing its technology across scales for R&D, high throughput screening and clinical cell therapies.